

SPINE SAFETY CAUTIONARY NOTICE:

**Information for Healthcare Professionals:  
Drug Safety Labeling Changes -  
OxyContin (oxycodone hydrochloride) controlled-release tablets**

According to MedWatch, FDA notified healthcare professionals that changes have been made to the labeling of OxyContin to include the addition of 60-mg strength to opioid tolerance language throughout the label. The revised PRECAUTIONS indicates the following:

**PRECAUTIONS**

***Drug-Drug Interactions***

- Oxycodone is metabolized in part by cytochrome P450 2D6 and cytochrome P450 3A4 and in theory can be affected by other drugs.

Read the complete summary of MedWatch safety labeling changes at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm187070.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.